179 related articles for article (PubMed ID: 3288477)
1. A double-blind study of bromocriptine and L-dopa in de novo Parkinson's disease. Short-term results.
Riopelle RJ; Gawel MJ; Libman I; King DB; McLean DR; Paulseth R; Raphy B; Bouchard S
Eur Neurol; 1988; 28 Suppl 1():11-4. PubMed ID: 3288477
[TBL] [Abstract][Full Text] [Related]
2. A comparison of bromocriptine (Parlodel) and levodopa-carbidopa (Sinemet) for treatment of "de novo" Parkinson's disease patients.
Libman I; Gawel MJ; Riopelle RJ; Bouchard S
Can J Neurol Sci; 1987 Nov; 14(4):576-80. PubMed ID: 3319120
[TBL] [Abstract][Full Text] [Related]
3. Bromocriptine in the treatment of Parkinson's disease: a double-blind study against L-dopa/carbidopa.
Gawel M; Riopelle R; Libman I; Bouchard S
Adv Neurol; 1987; 45():535-8. PubMed ID: 3548263
[No Abstract] [Full Text] [Related]
4. A progress report on the New Zealand Multicentre Parkinson's disease trial. A comparison of low-dose treatment with bromocriptine or L-dopa.
Wallis WE
Eur Neurol; 1988; 28 Suppl 1():9-10. PubMed ID: 3288479
[TBL] [Abstract][Full Text] [Related]
5. Bromocriptine versus placebo in levodopa treated patients with Parkinson's disease.
Gron U
Acta Neurol Scand; 1977 Sep; 56(3):269-73. PubMed ID: 333855
[TBL] [Abstract][Full Text] [Related]
6. [Combined treatment of the early stages of Parkinson's syndrome with bromocriptine and levodopa. The results of a multicenter study].
Fischer PA; Przuntek H; Majer M; Welzel D
Dtsch Med Wochenschr; 1984 Aug; 109(34):1279-83. PubMed ID: 6381019
[TBL] [Abstract][Full Text] [Related]
7. The Sydney multicentre study of Parkinson's disease. The first 18 months.
Hely MA; Morris JG; Rail D; O'Sullivan DJ; Williamson PM; Genge S; Reid WG; Broe GA
Med J Aust; 1987 Feb; 146(4):195-8. PubMed ID: 3553878
[TBL] [Abstract][Full Text] [Related]
8. Bromocriptine and the clinical spectrum of Parkinson's disease.
Riopelle RJ
Can J Neurol Sci; 1987 Aug; 14(3 Suppl):455-9. PubMed ID: 3676920
[TBL] [Abstract][Full Text] [Related]
9. The effect of deprenyl and levodopa on the progression of Parkinson's disease.
Olanow CW; Hauser RA; Gauger L; Malapira T; Koller W; Hubble J; Bushenbark K; Lilienfeld D; Esterlitz J
Ann Neurol; 1995 Nov; 38(5):771-7. PubMed ID: 7486869
[TBL] [Abstract][Full Text] [Related]
10. Early combination of bromocriptine and levodopa in Parkinson's disease: a prospective randomized study of two parallel groups over a total follow-up period of 44 months including an initial 8-month double-blind stage.
Giménez-Roldán S; Tolosa E; Burguera JA; Chacón J; Liaño H; Forcadell F
Clin Neuropharmacol; 1997 Feb; 20(1):67-76. PubMed ID: 9037575
[TBL] [Abstract][Full Text] [Related]
11. Quantitative description of loss of clinical benefit following withdrawal of levodopa-carbidopa and bromocriptine in early Parkinson's disease.
Hauser RA; Holford NH
Mov Disord; 2002 Sep; 17(5):961-8. PubMed ID: 12360545
[TBL] [Abstract][Full Text] [Related]
12. The Parkinson-Control study: a 1-year randomized, double-blind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in Parkinson's disease.
Castro-Caldas A; Delwaide P; Jost W; Merello M; Williams A; Lamberti P; Aguilar M; Del Signore S; Cesaro P;
Mov Disord; 2006 Apr; 21(4):500-9. PubMed ID: 16267842
[TBL] [Abstract][Full Text] [Related]
13. Controversies in the therapy of Parkinson's disease.
Fahn S
Adv Neurol; 1996; 69():477-86. PubMed ID: 8615168
[TBL] [Abstract][Full Text] [Related]
14. An evaluation of bromocriptine in the treatment of Parkinson's disease.
Mackenzie RA; Lance JW
Clin Exp Neurol; 1978; 15():228-36. PubMed ID: 386307
[TBL] [Abstract][Full Text] [Related]
15. Treatment of Parkinson's disease: levodopa as the first choice.
Katzenschlager R; Lees AJ
J Neurol; 2002 Sep; 249 Suppl 2():II19-24. PubMed ID: 12375059
[TBL] [Abstract][Full Text] [Related]
16. Naltrexone, an opiate antagonist, fails to modify motor symptoms in patients with Parkinson's disease.
Rascol O; Fabre N; Blin O; Poulik J; Sabatini U; Senard JM; Ané M; Montastruc JL; Rascol A
Mov Disord; 1994 Jul; 9(4):437-40. PubMed ID: 7969211
[TBL] [Abstract][Full Text] [Related]
17. Low-dosage treatment in de novo patients with Parkinson's disease: a prospective study.
van der Drift JH
Adv Neurol; 1987; 45():529-34. PubMed ID: 3825731
[TBL] [Abstract][Full Text] [Related]
18. Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD.
Katzenschlager R; Head J; Schrag A; Ben-Shlomo Y; Evans A; Lees AJ;
Neurology; 2008 Aug; 71(7):474-80. PubMed ID: 18579806
[TBL] [Abstract][Full Text] [Related]
19. Low-dose bromocriptine in the early phases of Parkinson's disease.
Tolosa E; Blesa R; Bayes A; Forcadell F
Clin Neuropharmacol; 1987 Apr; 10(2):168-74. PubMed ID: 3332610
[TBL] [Abstract][Full Text] [Related]
20. [Long-term results of treatment of Parkinson's disease with bromocriptine and domperidone (author's transl)].
Agid Y; Quinn N; Lhermitte F
Rev Neurol (Paris); 1981; 137(1):49-51. PubMed ID: 7232966
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
